In a KEYNOTE 045 trial for pembrolizumab in patients with metastatic or locally advanced/unresectable UC that has recurred or progressed following platinum-based chemotherapy, the subgroup analysis of PD-L1 positive tumors (combined positive score (CPS), positive tumor cells, lymphocytes, and macrophages ≥ 1%) and strongly PD-L1 positive tumors (CPS ≥ 10%) was performed. The gene discussed is CD274; the disease is neoplasm.